HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sgouros, G. Search for Related Content PubMed PubMed Citation Articles by Sgouros, G.

Plasmapheresis in Radioimmunotherapy of Micrometastases: A Mathematical Modeling and Dosimetrical Analysis

Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York

Correspondence: For reprints contact: George Sgouros, PhD, Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021.

ABSTRACT

The feasibility of combining plasmapheresis with a large administration of radiolabeled antibody in order to overcome the "binding-site" barrier to antibody penetration in targeting hematologically distributed micrometastases is examined. In such a strategy, intravenous administration of excess radiolabeled antibody, to saturate antigen sites on the cell cluster periphery, is followed by removal of unbound antibody from the plasma, by plasmapheresis, to reduce the absorbed dose to the red marrow. Plasma antibody kinetics are simulated by a non-linear compartmental model representing free and antigen-bound antibody. This provides the boundary condition for a model of antibody diffusion, saturable binding to and dissociation from antigen sites within a 200 µm diameter duster of tumor cells. Using these models, the absorbed dose to the red marrow and the absorbed dose profile across the cell cluster are calculated. Changes in marrow and cell duster absorbed dose from alterations in the onset time and rate of plasmapheresis are illustrated for antibody labeled with ¹²³I, ¹²⁵I and ¹³¹I. The results demonstrate that the "binding site" barrier may be overcome, yielding a 2- to 100-fold improvement in the cell duster absorbed dose for a given bone marrow absorbed dose.

This article has been cited by other articles:

				D. Emfietzoglou, K. Kostarelos, A. Papakostas, W.-H. Yang, A. Ballangrud, H. Song, and G. Sgouros Liposome-Mediated Radiotherapeutics Within Avascular Tumor Spheroids: Comparative Dosimetry Study for Various Radionuclides, Liposome Systems, and a Targeting Antibody J. Nucl. Med., January 1, 2005; 46(1): 89 - 97. [Abstract] [Full Text] [PDF]

				A. M. Ballangrud, W.-H. Yang, S. Palm, R. Enmon, P. E. Borchardt, V. A. Pellegrini, M. R. McDevitt, D. A. Scheinberg, and G. Sgouros Alpha-Particle Emitting Atomic Generator (Actinium-225)-Labeled Trastuzumab (Herceptin) Targeting of Breast Cancer Spheroids: Efficacy versus HER2/neu Expression Clin. Cancer Res., July 1, 2004; 10(13): 4489 - 4497. [Abstract] [Full Text] [PDF]

				A. M. Ballangrud, W.-H. Yang, D. E. Charlton, M. R. McDevitt, K. A. Hamacher, K. S. Panageas, D. Ma, N. H. Bander, D. A. Scheinberg, and G. Sgouros Response of LNCaP Spheroids after Treatment with an {{alpha}}-Particle Emitter (213Bi)-labeled Anti-Prostate-specific Membrane Antigen Antibody (J591) Cancer Res., March 1, 2001; 61(5): 2008 - 2014. [Abstract] [Full Text]